DJIA 17,265.99 109.14 0.64%
NASDAQ 4,593.43 31.24 0.68%
S&P 500 2,011.36 9.79 0.49%
market minute promo

Gilead Sciences (NASDAQ: GILD)

105.93 2.09 (2.01%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

GILD $105.93 2.01%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $104.63
Previous Close $103.84
Daily Range $104.10 - $106.50
52-Week Range $58.81 - $110.64
Market Cap $160.1B
P/E Ratio 23.39
Dividend (Yield) $0.00 (0.0%)
Volume 16,309,141
Average Daily Volume 14,392,836
Current FY EPS $7.26





Gilead Sciences (GILD) Description

Gilead Sciences created and sells the world’s top-selling HIV medications, Truvada and Atripla, and commands about 75% of the U.S. treatment market and more than 50% worldwide. Website:

News & Commentary Rss Feed

Is It Time to Buy Dividend Stock Bristol-Myers Squibb Co?

Bristol-Myers Squibb's share price has lagged behind its peers in recent months. Could this weakness present a compelling buying opportunity?

Sanofi & MyoKardia Ink Deal to Develop Cardiomyopathies - Analyst Blog

Bayer/Orion Progress with Prostate Cancer Drug ODM-201 - Analyst Blog

Gilead Science stumbles, but stays on its feet

Gilead: Still 50% Upside Left In The Stock

Gilead Sciences: The Recent Dip In Share Price Creates A Buying Opportunity

2 Columbia Growth Funds Notch Impressive Three-Month Performance

Gilead Sciences, inc. Stock's Incoming Game Changer

Gilead's Sovaldi sales could reach $10 billion this year, but sales could head even higher next year if the FDA approves its Sovaldi and ledipasvir combination drug.

3 Best Stocks for Investing in Biotech

Gilead Sciences, Celgene Corp, and BioMarin are three biotech industry companies that are revolutionizing how doctors treat patients.

Merck Posts Positive Data on Osteoporosis Drug Odanacatib - Analyst Blog

See More GILD News...

GILD's Top Competitors

GILD $105.93 (2.01%)
Current stock: GILD
AMGN $142.02 (0.93%)
Current stock: AMGN
CELG $93.27 (1.09%)
Current stock: CELG
$0.00 (0.00%)
Current stock: